Opko Health, Inc.
- UEI
- JSG4GCVBM155
- CAGE
- 5KMH6
- Primary NAICS
- 621511 Medical Laboratories
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Opko Health, Inc.
JSG4GCVBM155
- Bioreference Health LLC N7JNCQ8KKH97
- Opko Pharmaceuticals LLC LUZKWLW3T2K4
-
Opko Health, Inc.
JSG4GCVBM155
- SAM.gov registration date
- Website
- opko.com
- Founded
- 1991
- Employees
- 5K-10K
- Estimated annual revenue
- $1B-$10B
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Score testing | Veterans Integrated Service Network 23 | $37,200 | |
| Score lab tests | Veterans Integrated Service Network 23 | $55,200 | |
| 4K score PSA blood tests BPA | Veterans Integrated Service Network 23 | $81,000 | |
| 4K score PSA blood tests BPA | Veterans Integrated Service Network 23 | $70,200 | |
| 4K score PSA blood tests BPA | Veterans Integrated Service Network 23 | $83,400 |
About Opko Health, Inc.
Opko Health, Inc. is a diverse healthcare company registered in SAM.gov since 2009, operating as a for-profit corporate entity with multiple subsidiaries that provide specialized medical testing and pharmaceutical services to federal agencies. Through its subsidiaries Genedx, LLC and Bioreference Health LLC, the company delivers sophisticated genetic testing, laboratory diagnostics, and healthcare-related products to various federal agencies including the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Department of Veterans Affairs (VA). These services encompass genetic mutation analysis, genomic sequencing, pathology testing, and specialized clinical diagnostic services that support critical medical research and healthcare programs.
Opko Health's federal contract awards primarily involve providing specialized medical testing services across multiple domains. Through Genedx, the company has consistently secured purchase orders from NIH Clinical Center for genetic mutation analysis, exome and genome sequencing, and gene panel testing. Bioreference Health has been awarded significant contracts with the VA for anatomic pathology services in locations like Wilkes-Barre, Pennsylvania. During the COVID-19 pandemic, the company received substantial contracts from the CDC for serology testing, including a $5.76 million definitive contract for COVID-19 testing services. These contracts were predominantly firm fixed-price purchase orders and delivery orders, with no specific set-aside designations, demonstrating the company's ability to compete in open federal marketplace procurement.
Regarding federal grant awards, Opko Health has participated as a sub-recipient in research-focused grants, particularly in neurological research. The company has collaborated with institutions like Northwestern University and Massachusetts Eye And Ear Infirmary on specialized research projects. Specifically, the company has been involved in a Channelopathy-Associated Epilepsy Research Center, where Opko provides critical research support by designing experiments, supervising hybridization assay studies, analyzing data, and contributing to manuscript preparation and presentations. These sub-awards indicate the company's scientific expertise and willingness to support advanced medical research through collaborative grant mechanisms.
Opko Health holds multiple significant federal contract Indefinite Delivery Vehicles (IDVs) across different agencies. A notable IDV is a multiple-award Federal Supply Schedule contract with the Department of Veterans Affairs, valued at $19,469,960, covering drugs, pharmaceuticals, and hematology-related products through September 2028. Another key IDV is a single-award contract with NIH Clinical Center for mutation analysis services, valued at $1,012,384 and running through June 2024. The company also holds a multiple-award IDV with CDC Pittsburgh for surge serology testing, valued at $23,750,000, which was particularly critical during the COVID-19 pandemic. These IDVs demonstrate Opko Health's strategic positioning across federal healthcare and research procurement channels, offering flexible, specialized services to government agencies.
Quick answers
What is Opko Health, Inc.'s UEI?
Opko Health, Inc.'s Unique Entity ID (UEI) in SAM.gov is JSG4GCVBM155.
What is Opko Health, Inc.'s CAGE code?
Opko Health, Inc.'s CAGE code is 5KMH6.
What is Opko Health, Inc.'s primary NAICS code?
Opko Health, Inc.'s primary NAICS code is 621511 (Medical Laboratories).
Is Opko Health, Inc. registered in SAM.gov?
Opko Health, Inc.'s SAM.gov registration expired on November 3, 2021.
What is Opko Health, Inc.'s most recent federal award?
Opko Health, Inc.'s most recent federal contract award is Score testing (36C26321P0024), from Veterans Integrated Service Network 23, on March 16, 2021.
On GovTribe
See Opko Health, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors